Haemonetics Corporation (HAE)
Solvency ratios
| Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt-to-assets ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt-to-capital ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt-to-equity ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial leverage ratio | 2.58 | 2.79 | 2.87 | 2.81 | 2.29 | 2.33 | 2.25 | 2.27 | 2.37 | 2.42 | 2.56 | 2.36 | 2.48 | 2.51 | 2.58 | 2.65 | 2.49 | 1.83 | 2.12 | 2.35 |
Haemonetics Corporation has consistently maintained a very strong solvency position based on its solvency ratios.
1. Debt-to-assets ratio: The company has consistently reported a debt-to-assets ratio of 0.00, indicating that it has no debt relative to its total assets. This signifies a low financial risk as the company's assets are predominantly financed by equity.
2. Debt-to-capital ratio: Similar to the debt-to-assets ratio, the debt-to-capital ratio has also remained at 0.00 across all the periods. This further supports the notion that the company relies on equity financing rather than debt financing for its operations.
3. Debt-to-equity ratio: The debt-to-equity ratio has consistently been reported as 0.00, suggesting that the company's financial structure is skewed towards equity rather than debt. This indicates a conservative approach to financing and a lower risk of financial distress.
4. Financial leverage ratio: The financial leverage ratio has fluctuated slightly over the periods but has generally remained within a moderate range, with a peak at 2.87. This ratio indicates the proportion of the company's assets that are financed by debt. Despite some fluctuations, the ratio is not alarmingly high, and the company's financial leverage seems manageable.
In summary, Haemonetics Corporation exhibits a solid solvency position with very low debt levels relative to its assets and capital. The company's conservative financial structure and moderate financial leverage ratio indicate prudent financial management and a lower risk of insolvency.
Coverage ratios
| Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Interest coverage | 5.13 | 5.83 | 7.11 | 9.21 | 13.74 | 17.87 | 19.49 | 15.66 | 10.67 | 8.82 | 6.93 | 6.12 | 4.71 | 2.07 | 2.47 | 4.54 | 5.33 | 9.34 | 9.36 | 8.28 |
Haemonetics Corporation's interest coverage ratio has displayed fluctuations over the reported periods. The interest coverage ratio indicates the company's ability to meet its interest obligations from its operating income.
Based on the data provided, the interest coverage ratio ranged from a high of 19.49 as of September 30, 2023, to a low of 2.07 as of December 31, 2021. A declining trend in the interest coverage ratio can be observed from December 31, 2021, to March 31, 2022, indicating a potential strain on the company's ability to cover its interest expenses.
Subsequently, there was an improvement in the ratio reaching 15.66 as of June 30, 2023, suggesting an enhanced capacity to meet interest payments. However, the ratio decreased in the following periods until March 31, 2025, where it stood at 5.13.
Overall, fluctuations in the interest coverage ratio for Haemonetics Corporation signify varying levels of financial risk regarding its ability to cover interest expenses from operating income. It is essential for investors and stakeholders to monitor this ratio closely to assess the company's financial health and debt repayment capacity.